Increased Permeability of the Blood-Brain Barrier to Chemotherapy in Metastatic Brain Tumors: Establishing a Treatment Paradigm
- 1 June 2007
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (16), 2306-2312
- https://doi.org/10.1200/jco.2006.10.0677
Abstract
There is no accepted standard of care for the chemotherapy treatment of metastatic brain tumors, which has been generally limited to lipophilic alkylators, which may not have efficacy against the tumor that metastasized to the brain. More than 50% of chemotherapy agents are natural product drugs, which are rarely used in the treatment of metastatic brain tumors because they are thought to not cross the blood-brain barrier (BBB). A major protein constituent in the BBB is P-glycoprotein (P-gp), which pumps natural product chemotherapy drugs and toxins out of the CNS. However, P-gp expression in the neovasculature of metastatic brain tumors is similar to the P-gp expression in the neovasculature of the primary, extracranial tumor. In contrast, gliomas have higher P-gp expression in their neovasculature, similar to the greater intrinsic expression of P-gp in normal brain vasculature. This decreased immunohistochemical expression of P-gp in the neovasculature of metastatic tumors, as well as our recent pharmacologic demonstration of increased tissue concentrations of paclitaxel in metastatic brain tumors compared with gliomas, support the idea that the choice of chemotherapy agents should be based on the histologic origin of the metastatic brain tumor and not on the lipophilicity of the drug. Our hypothesis is that metastatic brain tumors from tumors with intrinsically low P-gp expression (eg, lung, melanoma, and untreated breast) may be more permeable to natural product chemotherapy drugs than gliomas. This information could lead to a paradigm shift in the use of natural product drugs for metastatic brain tumors.Keywords
This publication has 57 references indexed in Scilit:
- Overexpression of ADAM9 in Non-Small Cell Lung Cancer Correlates with Brain MetastasisCancer Research, 2004
- Vascular Endothelial Growth Factor Modulates the Transendothelial Migration of MDA-MB-231 Breast Cancer Cells through Regulation of Brain Microvascular Endothelial Cell PermeabilityJournal of Biological Chemistry, 2003
- The seed and soil hypothesis: vascularisation and brain metastasesThe Lancet Oncology, 2002
- Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGFScience, 1999
- The Biology of Melanoma Brain MetastasisCancer and Metastasis Reviews, 1999
- Brain metastases: Histology, multiplicity, surgery, and survivalCancer, 1996
- Predilection of brain metastasis in gray and white matter junction and vascular border zonesCancer, 1996
- Distribution of Brain MetastasesArchives of Neurology, 1988
- Changes of the blood-brain barrier in experimental metastatic brain tumorsJournal of Neurosurgery, 1983
- An Experimental Model for Cerebral Metastasis Preliminary Light and Ultrastructural StudiesJournal of Neuropathology and Experimental Neurology, 1979